Member Info for Burble

Agreed - this feels like an absolute step change away from a university spin out to a commercial pharma company. The entire slide deck so far, graphics and even that first snapshot slide feels very professional and a breath of fresh air.

If these webinars are run in a similar way to the ones we run at work, speakers agree the question set beforehand.

As such, I think it's telling that Stephen Gunnion asks the question 'What are the key benefits of Scancell's non-personalised medicine?'

PL then goes on to describe very succinctly the three areas he sees as a benefit.

The product is off the shelf, straightforward to manufacture, low cost to manufacture and made available quickly to patients. All things that have been highlighted on this board and by others on other boards.

Clinically it is showing compelling results in combination with the double checkpoint inhibitors with no additional safety issues and can be added to other therapies. The latter comment makes me wonder whether this opens up avenues for SCIB/iSCIB1+ to be used in combination with other CPIs as they become available/used - i.e. future proofing by not needing specifically to be used with ipi/nivo.

Then PL goes on to talk about the dual mechanism of action highlighting the long term immune control. I’m curious as to whether this is a hint that mRNA vaccines do not provide that level of long term control and need repetitive dosing?


Then a second thing to note - the question around what excites you most about the companies potential?

He genuinely believes in the company. This for me is key. He talks about compelling products, excellent data emerging and the strong team he has around him in the organisation with strong immunology/translational medicines expertise. And the strongly committed board and investors. 

'I am excited about what we *have* to do in 2025, we have the team and the resources to execute the plan and we will do that.'

Interesting choice of words. But to me, hearing him speak, he comes across as meaning business, understanding the science but not needing to talk at length about the science. Instead taking a more business approach. Succinct, to the point, logical to follow and I think that will help going forward because new investors will understand things possibly more than they do currently.

I would usually think in this context it would be calendar year.

Everything does point to the back end of this year.

I’m glad that the iSCIB1+ cohort is basically nearly full. Now that SCIB1 is full, that shouldn’t take long to fill up and then the 25 week wait begins. So all things going smoothly that’s basically mid July to end of August we would have a full iSCIB1+ with a full 25 weeks of data. Pointing to a late Q or Q4 decision.

The ID delivery cohort I guess would do two things - clarify which delivery mechanism to go with (this could complicate/delay things if a slightly different formulation is required for ID over IM. Would be good to understand whether that is the case). In addition it will give us bigger number of data points - which could add weight to any partnering deal.

A brief scan through. Nothing massively jumps out at me though I haven’t had a chance to fully go through it with a fine tooth comb.

A few things did jump out at me thought

‘Manufacturing processes for iSCIB1+ improved in preparation for late stage development.’

This is interesting - does this suggest they have already decided to go ahead with iSCIB1+ for later trials anticipating they would need an increase in supply. Or are they just covering bases? Curious why you would only focus on one and not improving both SCIB1 and iSCIB1+ in parallel?

Long-term stability data shows that SCIB1/iSCIB1+ remains stable at -20 ± 5°C. This is the first time IIRC that this has been stated (I spoke to Callum Scott at length at the AGM about how the stability at higher temperature storage was a really important thing to highlight and personalised mRNA medicines struggled due to the low temps needed.)

Following the data, we plan to progress to a randomised study on the path to registration, whilst evaluating partnering, out-licensing and further financing options? I hope for our sake the latter doesn’t mean more dilution. But given our history, it wouldn’t surprise me.

Modi-1 - interesting that we never hear full details of the other disease indications that have been targeted in the original clinical trial protocol. I wonder why this is and why we never get a full update on moditope like we seem to do on the SCOPE trial.

Quick question Johnyw.

If Scancell’s IPO on AIM according to Calculus was in 2010

(https://calculuscapital.com/investment/scancell/#:~:text=Scancell%20was%20founded%20in%201997,on%20AIM%20in%20July%202010.).

Can you explain how this has been a twenty year plus investment for you/your family? That would suggest you were invested in the company in the early 2000s.

Agree - I believe/hope we may see a step change in the approach to talking about progress, opportunities and the business as a whole. I think the focus may be less on the great science and more on the business side of things.

Seems you were on the money with this one given today’s RNS!

And an opportunity to hear from our new CEO.

Depending on when results are released, he could be able to talk about the most upto date data from the SCOPE trial.

Agree with all the below. To me it's less the results i'm interested in and more what the commentary that goes with it says (or doesn't say as the case may be).

I would think ae should get notice of interim results this week and then publication the following week.

Will be interesting to see how these look given they will be the first with our new CEO at the helm.

Some quite pertinent statements also made by other executives. I’ve selected a few as I feel these reflect SCLP and our positioning, offering, management etc. here’s hoping we reach the inflection point during 2025 when a nice biotech/pharma bull market is in full swing! Could work out in our favour given what’s said in the linked article.

“Pharma’s interest in novel mechanisms of action, increasingly precise therapeutic targeting, and scalable scientific approaches remains steadfast,”

“I feel optimistic about the industry’s appetite for financing, especially with clinical validation”

“These breakthroughs highlight how even in a field as complex as biopharma, persistence and innovation can transform lives.”

““The biotech industry has endured nearly three challenging years, with smaller companies hit hardest by a lack of funding, minimal IPO activity, and an environment where even positive developments struggled to gain traction”

“Companies that weathered the dry spell are emerging stronger, poised for significant growth in 2025. These resilient players are set to drive M&A activity, forge strategic partnerships, and shape executive strategies as the industry rebounds and funding conditions continue to improve.”

“Add the patent cliff that begins to ramp in 2025”

“For a platform or an early-stage asset to compete for funds and partnerships, it will require very clear and crisp messages on differentiation, and a well-thought-out path forward with early risk-reduction steps.”

“In today’s challenging investment landscape, biotech companies must rigorously validate their science and data to derisk clinical trials and obtain insights into a broader range of applications for their therapeutic approaches,”

I seem to remember we were told it would be 80 multiples of 10p at some point ;-)

Empty - wasn’t Crusty’s post below saying we have CEO etc in attendance this year?

https://www.linkedin.com/posts/scancell-limited_cancervaccine-clinicaldevelopment-jpmhc25-activity-7282779619550724098-_btG?utm_medium=ios_app&utm_source=social_share_send&utm_campaign=copy_link

Agree, though dare I say the US patent being granted probably will have more of an effect than the trial results. Especially if the market doesn’t fully understand the ORR and trial design.

Seperately, I’m curious why our new CEO hasn’t been quoted in this RNS. Even if Christian and Nermeen’s quotes are linked to the trial, a quote from our new CEO wouldn’t go amiss with reference to the patent being granted.

It's also interesting how limited information has been forthcoming with regard to Modify trial. Yes we have had some light updates, but nothing particularly interesting.

I agree with Crusty, I would prefer things to be separate announcements with proper detail rather than just rolled into a single RNS. At least if we had a stream of news at semi-regular intervals it would mean that new investors saw what the company was doing and what they were trying to achieve rather than having these long gaps of radio silence following news which had previously resulted in a SP rise.

On the flip side, no news I guess is good news. So we hold the faith and continue to wait for our investments to grow.

An interesting article on large scale graphene production.

Wonder what the impact of this would be on Haydale.

https://www.bbc.co.uk/news/articles/cjwl257009zo

Happy Christmas and a good New Year to all of you. Wishing you all the very best for 2025. Thank you for your good conversations, interesting analysis and fun off topic chats.

I'm hoping next big announcement will be a full and detailed update on moditope trial. But suspect it'll be something more trivial.